[Docetaxel enables initial survival time lengthening].
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel